title: Maintenance of long-term remission using oral administration of low-dose etoposide in a patient demonstrating a relapse of blastic natural killer-cell lymphoma.
authors.forename: Y
authors.initials: Y
authors.lastname: Hatano
authors.forename: M
authors.initials: M
authors.lastname: Ogata
authors.forename: M
authors.initials: M
authors.lastname: Ohishi
authors.forename: T
authors.initials: T
authors.lastname: Anan
authors.forename: K
authors.initials: K
authors.lastname: Senba
authors.forename: T
authors.initials: T
authors.lastname: Yasumatsu
authors.forename: K
authors.initials: K
authors.lastname: Katagiri
authors.forename: K
authors.initials: K
authors.lastname: Kashima
authors.forename: S
authors.initials: S
authors.lastname: Yokoyama
authors.forename: J-I
authors.initials: JI
authors.lastname: Kadota
authors.forename: S
authors.initials: S
authors.lastname: Takayasu
authors.forename: S
authors.initials: S
authors.lastname: Fujiwara
mesh_terms: D000284:Administration, Oral; D000368:Aged; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage / Q000627:therapeutic use*; D001706:Biopsy; D005047:Etoposide / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D007694:Killer Cells, Natural; D016410:Lymphoma, T-Cell, Cutaneous / Q000188:drug therapy* / Q000473:pathology / Q000517:prevention & control; D008297:Male; D012074:Remission Induction / Q000379:methods; D055502:Secondary Prevention; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000517:prevention & control; D016896:Treatment Outcome
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D005047:Etoposide